The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both classes demonstrate remarkable efficacy in supporting glycemic control and facilitating substantial weight loss, key distinctions in t… Read More

The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting considerable weight reduction – they exhibit intriguing variations in their pharm… Read More